Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection

Streptococcus Pneumonia Clinical Trial

— RIPI  

Official title:

Evaluation of Post Infectious Inflammatory Reaction (PIIR) in a Retrospective Study Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04594785
• Other study ID #: RECHMPL20_0550
• Status: Recruiting
• Start date: October 1, 2020
• Est. completion date: December 30, 2021

Study information

• Verified date: October 2020
• Source: University Hospital, Montpellier
• Contact: Eric JEZIORSKI
• Phone: 04 67 33 57 98
• Email: e-jeziorski[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

As Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions. Some of them are delayed and provide Post infectious inflammatory reaction (PIIR), they are challenging for diagnosis and for management. Clinician have to avoid unnecessary antibiotic thearapy and in if necessary have to give immunosuppressive therapy. Except for rheumatic disease for group A streptococcus (GAS) infections there are not stanrdized diagnostic criteria and therapeutic protocol, and PIIR have probably a suboptimal management. In this context the investigators aim to explore PIIR in the 3 most frequent bacterial invasive infection in France, by a retrospective monocentric study. The investigators include all children betwwen 2012 and 2018 hospitalized for infections by Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and GAS invasive infections.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 30, 2021
• Est. primary completion date: December 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion criteria:

• Less than 18 years of age

• Fever associated with GAS, NM, or SP invasive infection

Exclusion criteria:

• age > 18 years

• Impossibility to obtain the consent of parents / legal representatives.

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Inflammation
• Meningitis
• Meningitis, Meningococcal
• Meningococcal Infections
• Neisseria Meningitides Meningitis
• Pneumonia
• Streptococcus Pneumonia
• Streptococcus Pyogenes Infection

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Predictors of PIIRs	Identified the predictors of PIIRs in order to find warning symptoms	1 day
Primary	Describe the frequency PIIRs	Describe the frequency PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection	1 day
Secondary	Characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection	Describe the characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection	1 day